JP5709522B2 - 新規イメージング法 - Google Patents

新規イメージング法 Download PDF

Info

Publication number
JP5709522B2
JP5709522B2 JP2010534461A JP2010534461A JP5709522B2 JP 5709522 B2 JP5709522 B2 JP 5709522B2 JP 2010534461 A JP2010534461 A JP 2010534461A JP 2010534461 A JP2010534461 A JP 2010534461A JP 5709522 B2 JP5709522 B2 JP 5709522B2
Authority
JP
Japan
Prior art keywords
formula
compound
contrast agent
group
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010534461A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011506273A (ja
JP2011506273A5 (enExample
Inventor
チェッティビ、サラ
ニュートン、ベン
ソルバッケン、マグネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of JP2011506273A publication Critical patent/JP2011506273A/ja
Publication of JP2011506273A5 publication Critical patent/JP2011506273A5/ja
Application granted granted Critical
Publication of JP5709522B2 publication Critical patent/JP5709522B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2010534461A 2007-11-19 2008-11-19 新規イメージング法 Expired - Fee Related JP5709522B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98884007P 2007-11-19 2007-11-19
GB0722650.9 2007-11-19
GB0722650A GB0722650D0 (en) 2007-11-19 2007-11-19 Novel imaging method
US60/988,840 2007-11-19
PCT/EP2008/065824 WO2009071444A2 (en) 2007-11-19 2008-11-19 Novel imaging method

Publications (3)

Publication Number Publication Date
JP2011506273A JP2011506273A (ja) 2011-03-03
JP2011506273A5 JP2011506273A5 (enExample) 2014-01-09
JP5709522B2 true JP5709522B2 (ja) 2015-04-30

Family

ID=38896533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010534461A Expired - Fee Related JP5709522B2 (ja) 2007-11-19 2008-11-19 新規イメージング法

Country Status (8)

Country Link
US (1) US8834843B2 (enExample)
EP (1) EP2219681A2 (enExample)
JP (1) JP5709522B2 (enExample)
CN (1) CN101951964B (enExample)
BR (1) BRPI0820430A2 (enExample)
GB (1) GB0722650D0 (enExample)
RU (1) RU2505316C2 (enExample)
WO (1) WO2009071444A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2571486C1 (ru) * 2014-11-05 2015-12-20 Общество с ограниченной ответственностью "ДИАМЕД" Способ визуализации воспалений
EP3967704A4 (en) * 2019-06-11 2022-08-31 FUJIFILM Corporation CYCLIC PEPTIDE, CELLULAR SCAFFOLDING MATERIAL, CELL SEPARATION MATERIAL AND CULTURE MEDIUM

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL159310A0 (en) 2001-07-10 2004-06-01 Amersham Health As Peptide-based compounds
US20040223912A1 (en) * 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
GB0317815D0 (en) * 2003-07-30 2003-09-03 Amersham Health As Imaging agents
DE602004014795D1 (de) * 2003-10-01 2008-08-14 Merck Patent Gmbh Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel
DE602005025911D1 (de) * 2004-11-22 2011-02-24 Ge Healthcare As Kontrastmittel für eine extrazelluläre matrix
WO2006073314A1 (en) 2005-01-06 2006-07-13 Ge Healthcare As Optical imaging
US20080206151A1 (en) 2005-04-25 2008-08-28 Alan Cuthbertson Liposomes
EP1996013A4 (en) * 2005-09-21 2010-03-10 Dask Technologies Llc METHODS AND COMPOSITIONS FOR FUNCTIONALITY OF ORGANS AND TISSUES
GB0524987D0 (en) * 2005-12-08 2006-01-18 Ge Healthcare Ltd Novel imaging agents for fibrosis
WO2007148074A1 (en) 2006-06-21 2007-12-27 Hammersmith Imanet Limited Chemical methods and apparatus

Also Published As

Publication number Publication date
WO2009071444A2 (en) 2009-06-11
GB0722650D0 (en) 2007-12-27
WO2009071444A9 (en) 2009-10-01
JP2011506273A (ja) 2011-03-03
BRPI0820430A2 (pt) 2015-05-26
CN101951964B (zh) 2013-05-29
RU2010119187A (ru) 2011-12-27
RU2505316C2 (ru) 2014-01-27
CN101951964A (zh) 2011-01-19
US8834843B2 (en) 2014-09-16
EP2219681A2 (en) 2010-08-25
US20100316565A1 (en) 2010-12-16
WO2009071444A3 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
CN101454026B (zh) 成像剂
JP5308829B2 (ja) 癌の画像化および処置
US20080267882A1 (en) Imaging compounds, methods of making imaging compounds, methods of imaging, therapeutic compounds, methods of making therapeutic compounds, and methods of therapy
CZ20032564A3 (cs) Značené antagonisty receptoru makrofágového lapače pro zobrazování atherosklerosy a citlivých plaků
AU2003303714B2 (en) Improved linkers for radiopharmaceutical compounds
WO2019092242A1 (en) A double-labeled probe for molecular imaging and use thereof
JP2011520971A (ja) ガストリン放出ペプチド化合物
CN109316609B (zh) 选择患者的方法
US20250066417A9 (en) New peptide-based diagnostic and therapeutic agents
JP5709522B2 (ja) 新規イメージング法
JP2008528672A (ja) カスパーゼ−３基質含有造影剤
US20240115744A1 (en) Fibrin-binding compounds for imaging and treatment
JP2008509921A (ja) 内皮特異的な生体内伝達のターゲティング剤としての熱ショックタンパク質
KR20220152322A (ko) 생체내 알파-v-베타-6-인테그린 접근을 위한 환형 펩타이드 및 그의 컨쥬게이트
AU2010258599B2 (en) PET imaging of fibrogenesis
US20230295227A1 (en) Compounds for use in diagnosis and/or monitoring of fibrosis
WO2023104794A1 (en) Linker technology for reduced renal retention
WO2025061971A1 (en) Functionalized peptides for in-vivo addressing of pd-l1 expression
AU2009272810A1 (en) Treatment monitoring

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131009

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131108

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20131108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141010

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150303

R150 Certificate of patent or registration of utility model

Ref document number: 5709522

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees